Prilenia Plans To Continue With Pridopidine In ALS Despite Platform Study Miss

 
• By Joseph Haas

Pridopidine is the latest ALS drug candidate to miss the primary endpoint in the HEALEY-ALS platform study, but the S1R agonist did indicate potential benefits in speech and a key biomarker of the disease.

Neurodegeneration
Prilenia still hopes to advance pridopidine in ALS • Source: Shutterstock

More from Clinical Trials

More from R&D